Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Miocamycin-containing triple therapy for H. pylori infection.
Helicobacter
August 2013
Dipartimento di Medicina Clinica e Sperimentale, University of Sassari, Sassari, Italy.
Introduction: In Northern Sardinia, one-week triple standard therapies containing a proton-pump inhibitor and two antibiotics for H. pylori infection have an average cure rate of 57% largely due to a high prevalence of antimicrobial resistance. The efficacy of miocamycin-containing treatment for 10 days was evaluated.
View Article and Find Full Text PDFInfluence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres.
J Pharm Sci
April 2011
Department of Drug Sciences, University of Sassari, Sassari 07100, Italy.
Intranasal delivery is an alternative method to target therapeutics to the central nervous system. In the present study, chitosan glutamate (CG)-based mucoadhesive microspheres containing rokitamycin (RK) were prepared by spray-drying and in vitro characterization. Moreover, the influence of CG on RK absorption in bloodstream and cerebrospinal fluid (CSF) was evaluated after nasal administration to rats.
View Article and Find Full Text PDFNew chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration.
J Pharm Sci
December 2009
Department of Drug Sciences, University of Sassari, via Muroni 23/A, 07100 Sassari, Italy.
Acanthamoeba spp. are the causative agents of granulomatous amoebic encephalitis (GAE) and amoebic keratitis. Recent studies performed by Rassu et al.
View Article and Find Full Text PDFTherapeutic effect of rokitamycin in vitro and on experimental meningoencephalitis due to Naegleria fowleri.
Int J Antimicrob Agents
November 2008
Department of Microbiology and Department of Molecular Science & Technology, Ajou University School of Medicine, Suwon 443-721, Republic of Korea.
Inhalation of freshwater containing the free-living amoeba Naegleria fowleri leads to a potentially fatal infection known as primary amoebic meningoencephalitis (PAME). Amphotericin B is the only agent with clinical efficacy in the treatment of PAME in humans, however this drug is often associated with adverse effects on the kidney and other organs. In an attempt to select other useful therapeutic agents for treating PAME, the amoebicidal activities of antibacterial agents including clarithromycin, erythromycin, hygromycin B, neomycin, rokitamycin, roxithromycin and zeocin were examined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!